Shionogi To Buy U.S. Specialty Drug Maker Victory Pharma
This article was originally published in PharmAsia News
Shionogi's U.S. unit Sciele Pharma announced a plan to pay $150 million to acquire Victory Pharma, a U.S. pharmaceutical company specializing in pain drugs. The deal is expected to complete next month. The addition of Victory will further strengthen Shionogi's presence in the pain market, which has been one of the target therapeutic areas for the company. Shionogi also plans to introduce new products through Sciele. (Click here for more - Japanese language
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.